Zoomlion New Material Technology Co., Ltd. is a wholly-owned subsidiary of Zoomlion. Formerly m-tec, a German company founded in 1978. As the world’s leading supplier of dry mix mortar materials and equipment…
Shandong Chambroad Holding Group Co., Ltd.
Founded on July 08, 2020, MediLink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and related technologies. MediLink has developed the latest generation of Tumor Microenvironment Activable Linker-payload (TMALIN®) novel ADC platform technology with independent intellectual property rights, which can achieve high DAR value homogeneity with stable coupling. Further improve the therapeutic window of ADC drugs and enhance the therapeutic effect of ADC drugs against tumors, aiming to bring better treatment plans for cancer patients around the world.
Eternal Material Technology: Driving Digital Transformation with iLabPower and AI Integration
Founded on July 08, 2020, MediLink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and related technologies. MediLink has developed the latest generation of Tumor Microenvironment Activable Linker-payload (TMALIN®) novel ADC platform technology with independent intellectual property rights, which can achieve high DAR value homogeneity with stable coupling. Further improve the therapeutic window of ADC drugs and enhance the therapeutic effect of ADC drugs against tumors, aiming to bring better treatment plans for cancer patients around the world.
Guangdong BAWEI Biotechnology Corporation
Founded on July 08, 2020, MediLink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and related technologies. MediLink has developed the latest generation of Tumor Microenvironment Activable Linker-payload (TMALIN®) novel ADC platform technology with independent intellectual property rights, which can achieve high DAR value homogeneity with stable coupling. Further improve the therapeutic window of ADC drugs and enhance the therapeutic effect of ADC drugs against tumors, aiming to bring better treatment plans for cancer patients around the world.
Zhuhai United Laboratories
Founded on July 08, 2020, MediLink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and related technologies. MediLink has developed the latest generation of Tumor Microenvironment Activable Linker-payload (TMALIN®) novel ADC platform technology with independent intellectual property rights, which can achieve high DAR value homogeneity with stable coupling. Further improve the therapeutic window of ADC drugs and enhance the therapeutic effect of ADC drugs against tumors, aiming to bring better treatment plans for cancer patients around the world.
Shanghai Xihua Pharmaceutical
Founded on July 08, 2020, MediLink Therapeutics is an innovative drug development company focusing on antibody-drug conjugates (ADC) and related technologies. MediLink has developed the latest generation of Tumor Microenvironment Activable Linker-payload (TMALIN®) novel ADC platform technology with independent intellectual property rights, which can achieve high DAR value homogeneity with stable coupling. Further improve the therapeutic window of ADC drugs and enhance the therapeutic effect of ADC drugs against tumors, aiming to bring better treatment plans for cancer patients around the world.